Due to the exceptionally high plasma protein binding (>99.9%) of<unk> 's metabolite, tizoxanide, the concurrent use of<unk>  with other highly plasma protein-bound drugs with narrow therapeutic indices (e.g., warfarin) increases the risk of drug toxicity. In vitro evidence suggests that<unk>  does not affect the CYP450 system.
Nitazoxanide
Diloxanide
Secnidazole
Benznidazole
Fexinidazole
Tinidazole
Metronidazole
Oxytetracycline